An Australian stem cell and regenerative medicine company
About Us
About Us
What We Do
Board Of Directors
Management
Scientific Advisors
Corporate Governance
Company History
Clinical Development
Graft-versus-host-disease
Osteoarthritis
Acute respiratory distress syndrome
Diabetic Wounds
Renal transplantation
Pre-clinical Development
Asthma
Heart Attack
Coronary Artery Disease
Brain Cancer
Sepsis
Critical Limb Ischemia
Idiopathic pulmonary fibrosis
Science & Technology
Cymerus Technology
About MSCs
About iPSCs
Science Publications
Investors
Stock Information
ASX Announcements
Financial Reports
Presentations
Corporate Governance
Analyst Research
Investor FAQs
Right to Receive Documents
Newsroom
FAQ
Company FAQs
Investor FAQs
Contact Us
December 20, 2024
Euroz Hartleys update: "FDA Approves First Ever MSC Therapy"
View Report
December 20, 2024
MST Access update: "FDA approves first MSC product"
View Report
December 18, 2024
MST Access update: "Positive Diabetic Foot Ulcer Data"
View Report
December 16, 2024
Euroz Hartleys update: "Phase 1 DFU Success; Funding Secured"
View Report
November 06, 2024
Euroz Hartleys intitiates coverage: "Unlimited Cells, Unlimited Possibilities"
View Report
‹
1
2
3
4
5
6
7
8
9
10
11
›